



A Discussion of The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease

Hosted by Jason T. Jacobson, MD, FHRS

Article Information:

Article for Discussion: [The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease](#)

Authors: Soroosh Kiani, MD, MS, Michael N. Sayegh, MS, PHD, Rand Ibrahim, MD, Neal K. Bhatia, MD, Faisal M. Merchant, MD, Anand D. Shah, MD, Stacy B. Westerman, MD, MPH, David B. De Lurgio, MD, Anshul M. Patel, MD, Christine M. Thompkins, MD, Angel R. Leon, MD, Michael S. Lloyd, MD, Mikhael F. El-Chami, MD

Journal: JACC: Clinical Electrophysiology



Today's Host




Jason T. Jacobson, MD, FHRP
Westchester Medical Center-New York
Medical College



Today's Contributors:



**David J. Callans,
MD, FHRs, CCDS
Hospital of the
University of Pennsylvania**



**Gerald V Naccarelli, MD, FHRs
Pennsylvania State University
Milton S. Hershey Medical Center**



Disclosures:

David J. Callans, MD, FHRS, CCDS

- **Honoraria/Speaking/Consulting:** Heart Rhythm Society, Thermedical, AtriCure, Inc., Abbott Medical, Biosense Webster, Volta Medical, Mediasphere Medical, Coherex, American College of Cardiology, Best Doctors, Bayliss Medical, Biotronik, Boston Scientific, Impulse Dynamics USA
- **Fellowship Support:** Biosense Webster, Biotronik, Boston Scientific, Medtronic, Abbott
- **Other Financial Relationships:** Wolters Kluver

Jason T. Jacobson, MD, FHRS

- **Honoraria/Speaking/Consulting:** American College of Cardiology, Zoll Medical Corporation
- **Research:** Abbott, Phillips
- **Stock, Privately Held:** Atlas 5D

Gerald V Naccarelli, MD, FHRS

- **Honoraria/Speaking/Consulting:** Ascesion, Sanofi, GlaxoSmithKline, Milestone, InCarda Therapeutics





Thank you!